Breast Cancer Drug Analysis Flags Dementia Signals for Anastrozole in Women Over 50
A large pharmacovigilance analysis of FDA adverse event reports found no overall dementia risk signal for endocrine and targeted breast ...
A large pharmacovigilance analysis of FDA adverse event reports found no overall dementia risk signal for endocrine and targeted breast ...
A Mini Review finds that modest inverse associations between cancer and Alzheimer’s disease reflect interacting epidemiological, treatment and biological factors ...
The new phase 3 RxFINE-Low trial will test whether patients with low genomic risk but high anatomic risk early-stage breast ...
A nationwide U.S. insurance claims analysis presented at the ASTRO Annual Meeting found that fewer than 30 percent of early-stage ...
A preliminary study of 141 patients finds that the low-cost APIS Breast Cancer Subtyping Kit closely matches established molecular assays ...
A phase Ib/II trial testing famitinib added to dalpiciclib and fulvestrant in HR-positive, HER2-negative advanced breast cancer met early response ...
The new global phase III AFT-70 NAVIGATE trial will test whether ultrasensitive Signatera MRD blood monitoring can safely guide CDK4/6 ...
The largest real-world study of its kind shows that quantitative oestrogen and progesterone receptor levels, measured in recent tumour biopsies, ...
A new review synthesizes declining contralateral breast cancer incidence, evolving risk prediction models, the biology of second primary tumors, and ...
A new first-person account in the Journal of Cancer Survivorship describes the emotional toll of pregnancy planning and loss after ...
© 2025 Scienmag - Science Magazine
© 2025 Scienmag - Science Magazine